Primary medical therapy for BRAF V600E-mutant melanoma brain metastases—is this good enough?
Publications
FDA Grants LN-144 Fast Track Status for Melanoma
The FDA has granted LN-144, an adoptive cell therapy that uses tumor-infiltrating lymphocyte (TIL) technology developed by Iovance Biotherapeutics, a fast track designation for the treatment of patients with advanced melanoma.
Melanoma Journal Articles for August 2017
BMJ Case Reports 2017; doi:10.1136/bcr-2017-221430 Symbiotic lymph node metastasis from breast cancer and melanoma Molecular medicine Reports Grb2-associated binder 2 expression and its roles in uveal melanoma invasion Meiling Chen, Yuehua…
Read More Melanoma Journal Articles for July 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial